KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($2.47) per share for the quarter.

KALA BIO Trading Down 2.5 %

Shares of KALA opened at $7.03 on Thursday. The business’s 50-day moving average price is $7.74 and its 200-day moving average price is $6.77. KALA BIO has a twelve month low of $4.21 and a twelve month high of $11.20. The stock has a market cap of $42.82 million, a PE ratio of -0.56 and a beta of -2.19. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research report on Thursday, February 13th.

Insider Transactions at KALA BIO

In other news, CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the completion of the transaction, the chief executive officer now owns 280,076 shares of the company’s stock, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were acquired at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the acquisition, the insider now directly owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. This represents a 40.18 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 9,506 shares of company stock valued at $72,531. 8.32% of the stock is owned by corporate insiders.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.